El impacto clínico de los efectos fisiológicos de la eritropoyetina y de los agentes estimulantes de la eritropoyetina en la incidencia de malignidad, trombosis e hipertensión

Más allá de la anemia

Translated title of the contribution: The clinical impact of the physiological effects of erythropoietin and erythropoietin-stimulating agents on the incidence of malignancy, thrombosis and hypertension: Beyond anaemia

L. M. Ortega, Gabriel Contreras

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The glycoprotein hormone erythropoietin is an essential viability and growth factor for the erythrocytic progenitors. EPO signalling involves tyrosine phosphorylation of the homodimeric EPO receptor and subsequent activation on intracellular proteins, kinases and transcription factors. Treatment with erythropoietic stimulating agents (ESA) or ecombinant human EPO (rHuEPO) is efficient and safe in improving the management of the anaemia associated with chronic kidney disease, and allowing avoidance of transfusions with blood products. However, the unanticipated increase in mortality found in recent randomized studies is prompting a reassessment of this view. The present review will show what is known about the physiology of this plasma factor that, it is now clear, is more than just an erythrocyte production factor, and its pleitropic effects influencing the incidence of malignancy, thrombosis, hypertension and retinopathy.

Original languageSpanish
Pages (from-to)288-294
Number of pages7
JournalNefrologia
Volume29
Issue number4
DOIs
StatePublished - Dec 31 2009

Fingerprint

Erythropoietin
Chronic Renal Insufficiency
Blood Transfusion
Protein Kinases
Tyrosine
Anemia
Intercellular Signaling Peptides and Proteins
Glycoproteins
Thrombosis
Transcription Factors
Erythrocytes
Phosphorylation
Hormones
Hypertension
Mortality
Incidence
Neoplasms
Therapeutics

Keywords

  • Erythropoietic stimulating agent
  • Erythropoietin
  • Glycoprotein
  • Hypertension
  • Malignancy
  • Recombinant human erythropoietin
  • Thrombosis

ASJC Scopus subject areas

  • Nephrology

Cite this

@article{46aa3dcd547f45f5939307281a9b4ccb,
title = "El impacto cl{\'i}nico de los efectos fisiol{\'o}gicos de la eritropoyetina y de los agentes estimulantes de la eritropoyetina en la incidencia de malignidad, trombosis e hipertensi{\'o}n: M{\'a}s all{\'a} de la anemia",
abstract = "The glycoprotein hormone erythropoietin is an essential viability and growth factor for the erythrocytic progenitors. EPO signalling involves tyrosine phosphorylation of the homodimeric EPO receptor and subsequent activation on intracellular proteins, kinases and transcription factors. Treatment with erythropoietic stimulating agents (ESA) or ecombinant human EPO (rHuEPO) is efficient and safe in improving the management of the anaemia associated with chronic kidney disease, and allowing avoidance of transfusions with blood products. However, the unanticipated increase in mortality found in recent randomized studies is prompting a reassessment of this view. The present review will show what is known about the physiology of this plasma factor that, it is now clear, is more than just an erythrocyte production factor, and its pleitropic effects influencing the incidence of malignancy, thrombosis, hypertension and retinopathy.",
keywords = "Erythropoietic stimulating agent, Erythropoietin, Glycoprotein, Hypertension, Malignancy, Recombinant human erythropoietin, Thrombosis",
author = "Ortega, {L. M.} and Gabriel Contreras",
year = "2009",
month = "12",
day = "31",
doi = "10.3265/NEFROLOGIA.2009.29.4.5282.EN.FULL",
language = "Spanish",
volume = "29",
pages = "288--294",
journal = "Nefrologia",
issn = "0211-6995",
publisher = "Grupo Aula Medica S.A.",
number = "4",

}

TY - JOUR

T1 - El impacto clínico de los efectos fisiológicos de la eritropoyetina y de los agentes estimulantes de la eritropoyetina en la incidencia de malignidad, trombosis e hipertensión

T2 - Más allá de la anemia

AU - Ortega, L. M.

AU - Contreras, Gabriel

PY - 2009/12/31

Y1 - 2009/12/31

N2 - The glycoprotein hormone erythropoietin is an essential viability and growth factor for the erythrocytic progenitors. EPO signalling involves tyrosine phosphorylation of the homodimeric EPO receptor and subsequent activation on intracellular proteins, kinases and transcription factors. Treatment with erythropoietic stimulating agents (ESA) or ecombinant human EPO (rHuEPO) is efficient and safe in improving the management of the anaemia associated with chronic kidney disease, and allowing avoidance of transfusions with blood products. However, the unanticipated increase in mortality found in recent randomized studies is prompting a reassessment of this view. The present review will show what is known about the physiology of this plasma factor that, it is now clear, is more than just an erythrocyte production factor, and its pleitropic effects influencing the incidence of malignancy, thrombosis, hypertension and retinopathy.

AB - The glycoprotein hormone erythropoietin is an essential viability and growth factor for the erythrocytic progenitors. EPO signalling involves tyrosine phosphorylation of the homodimeric EPO receptor and subsequent activation on intracellular proteins, kinases and transcription factors. Treatment with erythropoietic stimulating agents (ESA) or ecombinant human EPO (rHuEPO) is efficient and safe in improving the management of the anaemia associated with chronic kidney disease, and allowing avoidance of transfusions with blood products. However, the unanticipated increase in mortality found in recent randomized studies is prompting a reassessment of this view. The present review will show what is known about the physiology of this plasma factor that, it is now clear, is more than just an erythrocyte production factor, and its pleitropic effects influencing the incidence of malignancy, thrombosis, hypertension and retinopathy.

KW - Erythropoietic stimulating agent

KW - Erythropoietin

KW - Glycoprotein

KW - Hypertension

KW - Malignancy

KW - Recombinant human erythropoietin

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=70449700382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449700382&partnerID=8YFLogxK

U2 - 10.3265/NEFROLOGIA.2009.29.4.5282.EN.FULL

DO - 10.3265/NEFROLOGIA.2009.29.4.5282.EN.FULL

M3 - Article

VL - 29

SP - 288

EP - 294

JO - Nefrologia

JF - Nefrologia

SN - 0211-6995

IS - 4

ER -